SR One Capital Management, LLC

SR One Capital Management, LLC discloses dealings in 5 companies, chiefly ADARx Pharmaceuticals, Inc., Avalyn Pharma Inc. and Arcellx, Inc. We count 20 filings; the first trade dates from 8 February 2022 and the latest from 28 September 2026.

In open-market terms, that means 6 purchases worth €33.4M on one side and 2 sales worth €26.1M on the other. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 5 purchases and no sales.

A typical purchase (the median) is worth €5.2M. On 5 out of 5 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

The newest entry dates from 29 September 2026: a transaction, in ADARx Pharmaceuticals, Inc. The last insider purchase was made public on 29 September 2026, 19 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.